Case reports suggest that GLP-1 receptor agonists may impact FDG PET scan image quality. Thirty percent of myeloma lytic bone lesions are not detected via FGD PET, demonstrating the need for improved visualization. REASSURE assessed the long-term safety of radium-223, an alpha-emitting calcium mimetic that targets bone metastases.